Home World News A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in... World News A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 807 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs... September 21, 2020 New Mom Was Told a Lump in Her Breast Was “Built-Up... April 5, 2019 Holiday Coping and Enjoying December 17, 2021 Load more HOT NEWS Lucky 13-A Male Breast Cancer Story Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and... Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age...
